Diagnosis and pharmacotherapy of severe acute respiratory syndrome: What have we learn?. Tsang, K. W. T., Ooi, G. C., & Ho, P. L. European Respiratory Journal, 24(6):1025–1032, 2004. ![Diagnosis and pharmacotherapy of severe acute respiratory syndrome: What have we learn? [link]](https://bibbase.org/img/filetypes/link.svg "link")
Paper doi abstract bibtex In 2003, the onset of severe acute respiratory syndrome (SARS) caused worldwide chaos. Although SARS was eradicated by isolation towards the end of 2003, sporadic cases have been reported in Singapore, Taiwan and mainland China. In this review, SARS is discussed as a disease, as well as its diagnosis, management and pharmacotherapy. Respiratory physicians and healthcare professionals have to be aware of advances in the understanding of the diagnosis and management of severe acute respiratory syndrome. More research is required in order to prepare for if this respiratory infection recurs, but there are concerns that adequate pharmaceutical support may be lacking for the development of a vaccine. © ERS Journals Ltd. 2004.
@article{tsang_diagnosis_2004,
title = {Diagnosis and pharmacotherapy of severe acute respiratory syndrome: {What} have we learn?},
volume = {24},
issn = {0903-1936},
url = {http://erj.ersjournals.com/ http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emexb&NEWS=N&AN=39642296},
doi = {10.1183/09031936.04.00092004},
abstract = {In 2003, the onset of severe acute respiratory syndrome (SARS) caused worldwide chaos. Although SARS was eradicated by isolation towards the end of 2003, sporadic cases have been reported in Singapore, Taiwan and mainland China. In this review, SARS is discussed as a disease, as well as its diagnosis, management and pharmacotherapy. Respiratory physicians and healthcare professionals have to be aware of advances in the understanding of the diagnosis and management of severe acute respiratory syndrome. More research is required in order to prepare for if this respiratory infection recurs, but there are concerns that adequate pharmaceutical support may be lacking for the development of a vaccine. © ERS Journals Ltd. 2004.},
language = {English},
number = {6},
journal = {European Respiratory Journal},
author = {Tsang, K. W. T. and Ooi, G. C. and Ho, P. L.},
year = {2004},
keywords = {*severe acute respiratory syndrome/di [Diagnosis], *severe acute respiratory syndrome/dt [Drug Therapy], China, RNA directed DNA polymerase inhibitor/pd [Pharmacology], SARS coronavirus, Singapore, Taiwan, abdominal pain/si [Side Effect], anticoagulant agent/dt [Drug Therapy], anticoagulant agent/pd [Pharmacology], antithrombocytic agent/dt [Drug Therapy], antithrombocytic agent/pd [Pharmacology], asthenia/si [Side Effect], clinical trial, consensus interferon/cb [Drug Combination], consensus interferon/ct [Clinical Trial], consensus interferon/dt [Drug Therapy], consensus interferon/sc [Subcutaneous Drug Administration], controlled clinical trial, controlled study, corticosteroid/cb [Drug Combination], corticosteroid/dt [Drug Therapy], corticosteroid/pd [Pharmacology], diarrhea/si [Side Effect], drug eruption/si [Side Effect], enzyme inhibitor/dt [Drug Therapy], enzyme inhibitor/pd [Pharmacology], eradication therapy, glycyrrhizic acid/dt [Drug Therapy], glycyrrhizic acid/pd [Pharmacology], headache/si [Side Effect], heparin/dt [Drug Therapy], heparin/pd [Pharmacology], human, insomnia/si [Side Effect], lopinavir plus ritonavir/ae [Adverse Drug Reaction], lopinavir plus ritonavir/ct [Clinical Trial], lopinavir plus ritonavir/dt [Drug Therapy], lopinavir plus ritonavir/pd [Pharmacology], medical research, medical specialist, methylprednisolone/pd [Pharmacology], microsomal aminopeptidase/ec [Endogenous Compound], n acetyl s nitrosopenicillamine/dt [Drug Therapy], n acetyl s nitrosopenicillamine/pd [Pharmacology], nausea/si [Side Effect], nelfinavir/dt [Drug Therapy], nelfinavir/pd [Pharmacology], niclosamide/dt [Drug Therapy], niclosamide/pd [Pharmacology], nitroprusside sodium/dt [Drug Therapy], nitroprusside sodium/pd [Pharmacology], nonhuman, nucleoside analog/pd [Pharmacology], pancreatitis/si [Side Effect], patient care, peginterferon/dt [Drug Therapy], peginterferon/pd [Pharmacology], pentoxifylline/dt [Drug Therapy], pentoxifylline/pd [Pharmacology], priority journal, proteinase inhibitor/pd [Pharmacology], recombinant antigen/dt [Drug Therapy], recombinant antigen/pd [Pharmacology], reverse transcription polymerase chain reaction, review, sialidase inhibitor/pd [Pharmacology], tumor necrosis factor alpha/dt [Drug Therapy], tumor necrosis factor alpha/pd [Pharmacology], virus spike protein/ec [Endogenous Compound], virus vaccine},
pages = {1025--1032},
}
Downloads: 0
{"_id":"s8T4gXCGvrjgAcGSt","bibbaseid":"tsang-ooi-ho-diagnosisandpharmacotherapyofsevereacuterespiratorysyndromewhathavewelearn-2004","authorIDs":[],"author_short":["Tsang, K. W. T.","Ooi, G. C.","Ho, P. L."],"bibdata":{"bibtype":"article","type":"article","title":"Diagnosis and pharmacotherapy of severe acute respiratory syndrome: What have we learn?","volume":"24","issn":"0903-1936","url":"http://erj.ersjournals.com/ http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emexb&NEWS=N&AN=39642296","doi":"10.1183/09031936.04.00092004","abstract":"In 2003, the onset of severe acute respiratory syndrome (SARS) caused worldwide chaos. Although SARS was eradicated by isolation towards the end of 2003, sporadic cases have been reported in Singapore, Taiwan and mainland China. In this review, SARS is discussed as a disease, as well as its diagnosis, management and pharmacotherapy. Respiratory physicians and healthcare professionals have to be aware of advances in the understanding of the diagnosis and management of severe acute respiratory syndrome. More research is required in order to prepare for if this respiratory infection recurs, but there are concerns that adequate pharmaceutical support may be lacking for the development of a vaccine. © ERS Journals Ltd. 2004.","language":"English","number":"6","journal":"European Respiratory Journal","author":[{"propositions":[],"lastnames":["Tsang"],"firstnames":["K.","W.","T."],"suffixes":[]},{"propositions":[],"lastnames":["Ooi"],"firstnames":["G.","C."],"suffixes":[]},{"propositions":[],"lastnames":["Ho"],"firstnames":["P.","L."],"suffixes":[]}],"year":"2004","keywords":"*severe acute respiratory syndrome/di [Diagnosis], *severe acute respiratory syndrome/dt [Drug Therapy], China, RNA directed DNA polymerase inhibitor/pd [Pharmacology], SARS coronavirus, Singapore, Taiwan, abdominal pain/si [Side Effect], anticoagulant agent/dt [Drug Therapy], anticoagulant agent/pd [Pharmacology], antithrombocytic agent/dt [Drug Therapy], antithrombocytic agent/pd [Pharmacology], asthenia/si [Side Effect], clinical trial, consensus interferon/cb [Drug Combination], consensus interferon/ct [Clinical Trial], consensus interferon/dt [Drug Therapy], consensus interferon/sc [Subcutaneous Drug Administration], controlled clinical trial, controlled study, corticosteroid/cb [Drug Combination], corticosteroid/dt [Drug Therapy], corticosteroid/pd [Pharmacology], diarrhea/si [Side Effect], drug eruption/si [Side Effect], enzyme inhibitor/dt [Drug Therapy], enzyme inhibitor/pd [Pharmacology], eradication therapy, glycyrrhizic acid/dt [Drug Therapy], glycyrrhizic acid/pd [Pharmacology], headache/si [Side Effect], heparin/dt [Drug Therapy], heparin/pd [Pharmacology], human, insomnia/si [Side Effect], lopinavir plus ritonavir/ae [Adverse Drug Reaction], lopinavir plus ritonavir/ct [Clinical Trial], lopinavir plus ritonavir/dt [Drug Therapy], lopinavir plus ritonavir/pd [Pharmacology], medical research, medical specialist, methylprednisolone/pd [Pharmacology], microsomal aminopeptidase/ec [Endogenous Compound], n acetyl s nitrosopenicillamine/dt [Drug Therapy], n acetyl s nitrosopenicillamine/pd [Pharmacology], nausea/si [Side Effect], nelfinavir/dt [Drug Therapy], nelfinavir/pd [Pharmacology], niclosamide/dt [Drug Therapy], niclosamide/pd [Pharmacology], nitroprusside sodium/dt [Drug Therapy], nitroprusside sodium/pd [Pharmacology], nonhuman, nucleoside analog/pd [Pharmacology], pancreatitis/si [Side Effect], patient care, peginterferon/dt [Drug Therapy], peginterferon/pd [Pharmacology], pentoxifylline/dt [Drug Therapy], pentoxifylline/pd [Pharmacology], priority journal, proteinase inhibitor/pd [Pharmacology], recombinant antigen/dt [Drug Therapy], recombinant antigen/pd [Pharmacology], reverse transcription polymerase chain reaction, review, sialidase inhibitor/pd [Pharmacology], tumor necrosis factor alpha/dt [Drug Therapy], tumor necrosis factor alpha/pd [Pharmacology], virus spike protein/ec [Endogenous Compound], virus vaccine","pages":"1025–1032","bibtex":"@article{tsang_diagnosis_2004,\n\ttitle = {Diagnosis and pharmacotherapy of severe acute respiratory syndrome: {What} have we learn?},\n\tvolume = {24},\n\tissn = {0903-1936},\n\turl = {http://erj.ersjournals.com/ http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emexb&NEWS=N&AN=39642296},\n\tdoi = {10.1183/09031936.04.00092004},\n\tabstract = {In 2003, the onset of severe acute respiratory syndrome (SARS) caused worldwide chaos. Although SARS was eradicated by isolation towards the end of 2003, sporadic cases have been reported in Singapore, Taiwan and mainland China. In this review, SARS is discussed as a disease, as well as its diagnosis, management and pharmacotherapy. Respiratory physicians and healthcare professionals have to be aware of advances in the understanding of the diagnosis and management of severe acute respiratory syndrome. More research is required in order to prepare for if this respiratory infection recurs, but there are concerns that adequate pharmaceutical support may be lacking for the development of a vaccine. © ERS Journals Ltd. 2004.},\n\tlanguage = {English},\n\tnumber = {6},\n\tjournal = {European Respiratory Journal},\n\tauthor = {Tsang, K. W. T. and Ooi, G. C. and Ho, P. L.},\n\tyear = {2004},\n\tkeywords = {*severe acute respiratory syndrome/di [Diagnosis], *severe acute respiratory syndrome/dt [Drug Therapy], China, RNA directed DNA polymerase inhibitor/pd [Pharmacology], SARS coronavirus, Singapore, Taiwan, abdominal pain/si [Side Effect], anticoagulant agent/dt [Drug Therapy], anticoagulant agent/pd [Pharmacology], antithrombocytic agent/dt [Drug Therapy], antithrombocytic agent/pd [Pharmacology], asthenia/si [Side Effect], clinical trial, consensus interferon/cb [Drug Combination], consensus interferon/ct [Clinical Trial], consensus interferon/dt [Drug Therapy], consensus interferon/sc [Subcutaneous Drug Administration], controlled clinical trial, controlled study, corticosteroid/cb [Drug Combination], corticosteroid/dt [Drug Therapy], corticosteroid/pd [Pharmacology], diarrhea/si [Side Effect], drug eruption/si [Side Effect], enzyme inhibitor/dt [Drug Therapy], enzyme inhibitor/pd [Pharmacology], eradication therapy, glycyrrhizic acid/dt [Drug Therapy], glycyrrhizic acid/pd [Pharmacology], headache/si [Side Effect], heparin/dt [Drug Therapy], heparin/pd [Pharmacology], human, insomnia/si [Side Effect], lopinavir plus ritonavir/ae [Adverse Drug Reaction], lopinavir plus ritonavir/ct [Clinical Trial], lopinavir plus ritonavir/dt [Drug Therapy], lopinavir plus ritonavir/pd [Pharmacology], medical research, medical specialist, methylprednisolone/pd [Pharmacology], microsomal aminopeptidase/ec [Endogenous Compound], n acetyl s nitrosopenicillamine/dt [Drug Therapy], n acetyl s nitrosopenicillamine/pd [Pharmacology], nausea/si [Side Effect], nelfinavir/dt [Drug Therapy], nelfinavir/pd [Pharmacology], niclosamide/dt [Drug Therapy], niclosamide/pd [Pharmacology], nitroprusside sodium/dt [Drug Therapy], nitroprusside sodium/pd [Pharmacology], nonhuman, nucleoside analog/pd [Pharmacology], pancreatitis/si [Side Effect], patient care, peginterferon/dt [Drug Therapy], peginterferon/pd [Pharmacology], pentoxifylline/dt [Drug Therapy], pentoxifylline/pd [Pharmacology], priority journal, proteinase inhibitor/pd [Pharmacology], recombinant antigen/dt [Drug Therapy], recombinant antigen/pd [Pharmacology], reverse transcription polymerase chain reaction, review, sialidase inhibitor/pd [Pharmacology], tumor necrosis factor alpha/dt [Drug Therapy], tumor necrosis factor alpha/pd [Pharmacology], virus spike protein/ec [Endogenous Compound], virus vaccine},\n\tpages = {1025--1032},\n}\n\n","author_short":["Tsang, K. W. T.","Ooi, G. C.","Ho, P. L."],"key":"tsang_diagnosis_2004","id":"tsang_diagnosis_2004","bibbaseid":"tsang-ooi-ho-diagnosisandpharmacotherapyofsevereacuterespiratorysyndromewhathavewelearn-2004","role":"author","urls":{"Paper":"http://erj.ersjournals.com/ http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emexb&NEWS=N&AN=39642296"},"keyword":["*severe acute respiratory syndrome/di [Diagnosis]","*severe acute respiratory syndrome/dt [Drug Therapy]","China","RNA directed DNA polymerase inhibitor/pd [Pharmacology]","SARS coronavirus","Singapore","Taiwan","abdominal pain/si [Side Effect]","anticoagulant agent/dt [Drug Therapy]","anticoagulant agent/pd [Pharmacology]","antithrombocytic agent/dt [Drug Therapy]","antithrombocytic agent/pd [Pharmacology]","asthenia/si [Side Effect]","clinical trial","consensus interferon/cb [Drug Combination]","consensus interferon/ct [Clinical Trial]","consensus interferon/dt [Drug Therapy]","consensus interferon/sc [Subcutaneous Drug Administration]","controlled clinical trial","controlled study","corticosteroid/cb [Drug Combination]","corticosteroid/dt [Drug Therapy]","corticosteroid/pd [Pharmacology]","diarrhea/si [Side Effect]","drug eruption/si [Side Effect]","enzyme inhibitor/dt [Drug Therapy]","enzyme inhibitor/pd [Pharmacology]","eradication therapy","glycyrrhizic acid/dt [Drug Therapy]","glycyrrhizic acid/pd [Pharmacology]","headache/si [Side Effect]","heparin/dt [Drug Therapy]","heparin/pd [Pharmacology]","human","insomnia/si [Side Effect]","lopinavir plus ritonavir/ae [Adverse Drug Reaction]","lopinavir plus ritonavir/ct [Clinical Trial]","lopinavir plus ritonavir/dt [Drug Therapy]","lopinavir plus ritonavir/pd [Pharmacology]","medical research","medical specialist","methylprednisolone/pd [Pharmacology]","microsomal aminopeptidase/ec [Endogenous Compound]","n acetyl s nitrosopenicillamine/dt [Drug Therapy]","n acetyl s nitrosopenicillamine/pd [Pharmacology]","nausea/si [Side Effect]","nelfinavir/dt [Drug Therapy]","nelfinavir/pd [Pharmacology]","niclosamide/dt [Drug Therapy]","niclosamide/pd [Pharmacology]","nitroprusside sodium/dt [Drug Therapy]","nitroprusside sodium/pd [Pharmacology]","nonhuman","nucleoside analog/pd [Pharmacology]","pancreatitis/si [Side Effect]","patient care","peginterferon/dt [Drug Therapy]","peginterferon/pd [Pharmacology]","pentoxifylline/dt [Drug Therapy]","pentoxifylline/pd [Pharmacology]","priority journal","proteinase inhibitor/pd [Pharmacology]","recombinant antigen/dt [Drug Therapy]","recombinant antigen/pd [Pharmacology]","reverse transcription polymerase chain reaction","review","sialidase inhibitor/pd [Pharmacology]","tumor necrosis factor alpha/dt [Drug Therapy]","tumor necrosis factor alpha/pd [Pharmacology]","virus spike protein/ec [Endogenous Compound]","virus vaccine"],"metadata":{"authorlinks":{}}},"bibtype":"article","biburl":"https://bibbase.org/zotero/vincentwntu","creationDate":"2020-01-26T03:06:33.816Z","downloads":0,"keywords":["*severe acute respiratory syndrome/di [diagnosis]","*severe acute respiratory syndrome/dt [drug therapy]","china","rna directed dna polymerase inhibitor/pd [pharmacology]","sars coronavirus","singapore","taiwan","abdominal pain/si [side effect]","anticoagulant agent/dt [drug therapy]","anticoagulant agent/pd [pharmacology]","antithrombocytic agent/dt [drug therapy]","antithrombocytic agent/pd [pharmacology]","asthenia/si [side effect]","clinical trial","consensus interferon/cb [drug combination]","consensus interferon/ct [clinical trial]","consensus interferon/dt [drug therapy]","consensus interferon/sc [subcutaneous drug administration]","controlled clinical trial","controlled study","corticosteroid/cb [drug combination]","corticosteroid/dt [drug therapy]","corticosteroid/pd [pharmacology]","diarrhea/si [side effect]","drug eruption/si [side effect]","enzyme inhibitor/dt [drug therapy]","enzyme inhibitor/pd [pharmacology]","eradication therapy","glycyrrhizic acid/dt [drug therapy]","glycyrrhizic acid/pd [pharmacology]","headache/si [side effect]","heparin/dt [drug therapy]","heparin/pd [pharmacology]","human","insomnia/si [side effect]","lopinavir plus ritonavir/ae [adverse drug reaction]","lopinavir plus ritonavir/ct [clinical trial]","lopinavir plus ritonavir/dt [drug therapy]","lopinavir plus ritonavir/pd [pharmacology]","medical research","medical specialist","methylprednisolone/pd [pharmacology]","microsomal aminopeptidase/ec [endogenous compound]","n acetyl s nitrosopenicillamine/dt [drug therapy]","n acetyl s nitrosopenicillamine/pd [pharmacology]","nausea/si [side effect]","nelfinavir/dt [drug therapy]","nelfinavir/pd [pharmacology]","niclosamide/dt [drug therapy]","niclosamide/pd [pharmacology]","nitroprusside sodium/dt [drug therapy]","nitroprusside sodium/pd [pharmacology]","nonhuman","nucleoside analog/pd [pharmacology]","pancreatitis/si [side effect]","patient care","peginterferon/dt [drug therapy]","peginterferon/pd [pharmacology]","pentoxifylline/dt [drug therapy]","pentoxifylline/pd [pharmacology]","priority journal","proteinase inhibitor/pd [pharmacology]","recombinant antigen/dt [drug therapy]","recombinant antigen/pd [pharmacology]","reverse transcription polymerase chain reaction","review","sialidase inhibitor/pd [pharmacology]","tumor necrosis factor alpha/dt [drug therapy]","tumor necrosis factor alpha/pd [pharmacology]","virus spike protein/ec [endogenous compound]","virus vaccine"],"search_terms":["diagnosis","pharmacotherapy","severe","acute","respiratory","syndrome","learn","tsang","ooi","ho"],"title":"Diagnosis and pharmacotherapy of severe acute respiratory syndrome: What have we learn?","year":2004,"dataSources":["icTw8KRRMMANXJHRd"]}